Supplementary Figure 2 from Phase I Study of MEDI3726: A Prostate-Specific Membrane Antigen-Targeted Antibody–Drug Conjugate, in Patients with mCRPC after Failure of Abiraterone or Enzalutamide

Mutation profiles in ctDNA: truncating and/or pathogenic mutations in DDR or DDR-related pathway